Beyond vein diameter: pain phenotyping complements updated diagnostic criteria for female pelvic venous disorders Authors: Vinicius Adami Vayego Fornazari, Renato Abu Hana, Grit Armstrong Adler, Sara Lojo-Lendoiro, Nucelio Lemos, Gregory Kirk Lewis, Jean-Pierre Pelage, Gloria Maria Salazar Published: 2026 Dear Editor, We read with great interest the recent case–control study by Gonzales et al. demonstrating that gonadal vein (GV) diameter does not differentiate symptomatic from asymptomatic women and loses diagnostic value after adjustment for proximal venous outflow obstruction (VOO) and superficial varicosities [1]. Their findings represent more than a refinement of imaging criteria; they challenge the traditional assumption that pelvic venous disorders can be diagnosed primarily from venography or cross-sectional imaging. We believe this paradigm shift carries an important clinical implication for interventional radiologists (IRs): before venous anatomy is interpreted, the patient's pain phenotype must first be established. Chronic pelvic pain (CPP) is recognized by the International Association for the Study of Pain as a multifactorial condition in which visceral, nociceptive, neuropathic, and centrally sensitized mechanisms frequently coexist (Fig. 1) [2, 3]. Consequently, dilated ovarian or pelvic veins should not automatically be regarded as the cause of symptoms. Similar to incidental lumbar degenerative changes in patients with back pain, pelvic varices may represent coincidental findings unless they are concordant with a clinically compatible visceral pain phenotype. Anatomic and clinical overview of visceral, nociceptive, and neuropathic pelvic pain in women, illustrating the pelvic venous plexus and outflow pathways relevant to pelvic venous congestion syndrome, musculoskeletal/myofascial pain generators, and the pudendal/ilioinguinal nerve distributions. LE lower-extremity, VOO venous outflow obstruction We therefore propose a practical phenotype-based triage framework (Fig. 2) and a concise differential table (Table 1) to complement—not replace—the updated diagnostic criteria proposed by Gonzales et al. [1]. Rather than asking whether pelvic veins are dilated, clinicians should first determine whether the patient’s symptoms are predominantly visceral, nociceptive/somatic, or neuropathic. Diagnostic triage flowchart for chronic female pelvic pain in the interventional radiology setting. IR interventional radiology, MSK musculoskeletal, MRI magnetic resonance imaging, SI sacroiliac, VOO venous outflow obstruction, NIVL nonthrombotic iliac vein lesion, LRV left renal vein, LE lower-extremity, OVE ovarian/pelvic vein embolization. Phenotypes frequently overlap; discordant or refractory cases should be reassessed within a multidisciplinary chronic pelvic pain team Table 1Differential features of visceral, nociceptive, and neuropathic pelvic pain in womenFeatureVisceral pain(e.g., PVCS, endometriosis, adenomyosis)Nociceptive / somatic pain(e.g., myofascial pelvic floor pain, abdominal wall pain)Neuropathic pain(e.g., pudendal, ilioinguinal, iliohypogastric neuralgia)Pain characteristicsDull, cramping, aching, “heaviness” or pressure; poorly localized; often bilateralSharp, well-defined, reproducible with palpation or movement; usually unilateral and point-tenderBurning, shooting, electric; allodynia/hyperalgesia; paresthesiasMost frequent location / referral patternLower abdomen, suprapubic and adnexal (“ovarian point”); refers to low back, medial thigh, vulva; left ≥ right (left ovarian vein drains at a right angle into left renal vein)Abdominal wall (rectus, oblique), pelvic floor/levator ani, sacroiliac joint, pubic symphysis, hip; sharply localized — patient points with one fingerPudendal territory (perineum, vulva, anorectum); ilioinguinal/iliohypogastric/genitofemoral territory (groin, mons pubis, labia majora); dermatomal distributionTemporal patternCyclical with menses; worsens with prolonged standing and toward end of day; improves supine; postcoital achePositional/activity-related; reproducible with specific movement or sustained posture; constant baseline with mechanical flaresWorse with sitting; classically does not wake the patient at night (Nantes criteria); progressive, with intermittent paroxysmsAssociated symptomsDeep dyspareunia, dysmenorrhea, bloating, urinary urgency/frequency, vulvar and lower-limb varicositiesLocalized muscle spasm/guarding, restricted range of motion, superficial dyspareunia if pelvic floor involvedForeign-body/fullness sensation in vagina or rectum, superficial dyspareunia, bladder and bowel dysfunction, sexual dysfunctionPhysical examinationPost-coital ache and/or deep adnexal (“ovarian point”) tenderness — 94% sensitivity, 77% specificity for PVCS [2]; pain reproduced/worsened on standing or Valsalva; visible vulvar/perineal/thigh varicositiesPositive Carnett’s sign, palpable myofascial trigger points (“jump sign”), tender levator ani on vaginal exam, positive hip/SI provocative tests (FABER, FADIR)Positive Tinel’s sign over ischial spine/Alcock’s canal, dermatomal sensory changes on pinprick testing, tenderness along nerve courseValidated diagnostic toolsBeard clinical criteria (post-coital ache/ovarian point tenderness) [2]; Symptoms Varices Pathophysiology classification [2]; International Pelvic Pain Society history/exam form; visual analog scale, McGill Pain QuestionnaireCarnett’s sign (bedside test); diagnostic trigger-point injection with local anesthetic; digital pelvic floor tone/tenderness scoringNantes criteria (5 criteria) for pudendal neuralgia [4]; DN4 neuropathic pain questionnaire; diagnostic anesthetic nerve blockFirst-line imagingTransvaginal Doppler ultrasound and pelvic MRI/MR-venography; isolated GV diameter thresholds (≥ 6 mm reflux, or Coakley criteria) are poorly discriminating [1] — assess concurrently for proximal VOO (nonthrombotic iliac lesion, aortomesenteric left renal vein/“nutcracker” compression) and superficial (LE/vulvar) varicosities, the stronger predictors of symptomatic disease [1]; catheter venography remains the reference standard, also therapeuticCross-sectional imaging usually normal/nonspecific; musculoskeletal ultrasound for trigger points or hernia; MRI for sacroiliac joint, symphysis, or hip pathologyMR neurography (nerve caliber, T2 signal, entrapment site); high-resolution pelvic MRIExpected response to ovarian/pelvic vein embolization (OVE)Good to excellent (70–90% long-term relief) when proximal VOO and/or superficial escape-pathway varicosities corroborate the clinical picture — not when based on GV diameter alone [1, 2]; recurrence in 10–40%Poor / none — OVE not indicated; treating incidental venous dilation does not relieve musculoskeletal painNone — OVE not indicated; image-guided perineural nerve block is the analogous diagnostic and therapeutic IR toolTreatment relevant to IROvarian/internal iliac vein embolization (coils ± plug or sclerosant); adjunct hormonal suppression, NSAIDsReferral for pelvic floor physical therapy, trigger-point injection, botulinum toxin, musculoskeletal/pain medicineImage-guided pudendal or ilioinguinal nerve block, pulsed radiofrequency, neuromodulation; surgical decompression and gabapentinoids as adjuncts Differential features of visceral, nociceptive, and neuropathic pelvic pain in women Most frequent location / referral pattern Patients with visceral pain typically present with poorly localized pelvic heaviness, post-coital ache, positional worsening, and a cyclical component where the pain starts at ovulation and gets progressively worse in the second phase of the menstrual cycle, with the worst days being the two just before the menstrual period. This presentation becomes even more suggestive of Pelvic Congestion Syndrome when associated vulvar or lower-extremity varicosities. In this subgroup, venous imaging becomes clinically meaningful. However, isolated GV diameter should no longer be considered sufficient evidence of symptomatic pelvic venous disease. Imaging should instead be interpreted together with proximal VOO, superficial varicosities, and the SVP classification [4]. Conversely, nociceptive pain is characterized by focal tenderness, positive Carnett's sign, and myofascial trigger points. Neuropathic pain follows a dermatomal distribution and may fulfill the Nantes criteria. Validated screening tools including the DN4 questionnaire and the Central Sensitization Inventory (CSI) help identify neuropathic and centrally sensitized pain mechanisms unlikely to respond to ovarian vein embolization [3, 5, 6]. Importantly, our framework proposes a change in diagnostic sequence rather than new imaging criteria. Venous imaging should no longer be interpreted in isolation but as the final step of a structured clinical reasoning process that begins with pain phenotyping and proceeds to confirm clinical–imaging concordance. This approach may reduce the chances of ineffective embolization by improving patient selection, reserving intervention to those in whom anatomically similar venous abnormalities produce symptoms and avoiding it in those where these changes are clinically silent. The principal contribution of Gonzales et al. is therefore not simply demonstrating that gonadal vein diameter performs poorly as a diagnostic marker. Rather, it establishes that the diagnosis of pelvic venous disorders requires integration of imaging findings with a clinically validated visceral pain phenotype. Rather than asking whether pelvic veins are dilated, interventional radiologists should first ask whether the patient's pain behaves like visceral venous pain. Only when these two dimensions are concordant should endovascular treatment be considered. Acknowledgements Not applicable. Authors’ contributions All authors contributed to conceptualization, writing, images analysis and review. This case series images originate from the clinical practice from the corresponding author. Funding This study was not supported by any funding. Data availability All imaging and clinical information were retrospectively retrieved from the institutional PACS along with clinical observations acquired. Declarations Ethics approval and consent to participate This article does not contain any studies with human participants or animals performed by any of the authors. Consent for publication For this type of study, consent for publication is not required. Competing interests The authors declare that they have no competing interests. Footnotes Publisher’s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. References Associated Data Data Availability Statement All imaging and clinical information were retrospectively retrieved from the institutional PACS along with clinical observations acquired.